[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570209":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":31,"responsibleParty":168,"collaborators":19,"id":170,"slug":171,"hasResults":172,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":19,"eligibilityCriteria":176,"healthyVolunteers":172,"sex":177,"minAge":178,"maxAge":179,"enrollmentInfo":180,"targetDuration":19,"studyType":183,"phases":184,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":34,"whyStopped":19,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":203},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"YTB323","EXPERIMENTAL","YTB323 single intravenous (i.v.) infusion",[13],"Genetic: YTB323",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"GENETIC","CAR-T cell suspension for intravenous infusion",[9],null,[21],{"name":22,"affiliation":22,"role":23},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[25,29],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","1-888-669-6682","novartis.email@novartis.com",{"name":22,"role":26,"phone":30,"phoneExt":19,"email":19},"+41613241111",[32,54,71,87,104,115,123,131,141,149,160],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Univ Cali Irvine ALS Neuromuscular","RECRUITING","Orange","California","92868","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-117.85311,33.78779,{"lat":44,"lon":43},[47,51],{"name":48,"role":26,"phone":49,"phoneExt":19,"email":50},"UCI Alpha Clinic","(949) 824-3990","alphaclinic@hs.uci.edu",{"name":52,"role":53,"phone":19,"phoneExt":19,"email":19},"Ali Habib","PRINCIPAL_INVESTIGATOR",{"facility":55,"status":34,"city":56,"state":57,"zip":58,"country":38,"countryCode":39,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Wake Forest Univ School of Medicine","Winston-Salem","North Carolina","27157-1052",{"type":41,"coordinates":60},[61,62],-80.24422,36.09986,{"lat":62,"lon":61},[65,69],{"name":66,"role":26,"phone":67,"phoneExt":19,"email":68},"Katie Hoots","+1 336 716 1049","katrina.hoots@advocatehealth.org",{"name":70,"role":53,"phone":19,"phoneExt":19,"email":19},"Rachana Gandhi Mehta",{"facility":72,"status":34,"city":73,"state":74,"zip":75,"country":38,"countryCode":39,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Thomas Jefferson University","Philadelphia","Pennsylvania","19107",{"type":41,"coordinates":77},[78,79],-75.16362,39.95238,{"lat":79,"lon":78},[82,85],{"name":83,"role":26,"phone":19,"phoneExt":19,"email":84},"Natisha Muhammad","Natisha.Muhammad@jefferson.edu",{"name":86,"role":53,"phone":19,"phoneExt":19,"email":19},"Marinos Dalakas",{"facility":88,"status":34,"city":89,"state":90,"zip":91,"country":38,"countryCode":39,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Houston Methodist Hospital","Houston","Texas","77030",{"type":41,"coordinates":93},[94,95],-95.36327,29.76328,{"lat":95,"lon":94},[98,102],{"name":99,"role":26,"phone":100,"phoneExt":19,"email":101},"Jennifer Garrett","+1 346 238 4516","jmgarrett@houstonmethodist.org",{"name":103,"role":53,"phone":19,"phoneExt":19,"email":19},"Ericka Greene",{"facility":105,"status":34,"city":106,"state":19,"zip":107,"country":108,"countryCode":109,"cosmosGeoPoint":110,"geoPoint":114,"contacts":19},"Novartis Investigative Site","Bordeaux","33076","France","FR",{"type":41,"coordinates":111},[112,113],-0.58046,44.84124,{"lat":113,"lon":112},{"facility":105,"status":34,"city":116,"state":19,"zip":117,"country":108,"countryCode":109,"cosmosGeoPoint":118,"geoPoint":122,"contacts":19},"Brest","29200",{"type":41,"coordinates":119},[120,121],-4.48628,48.39029,{"lat":121,"lon":120},{"facility":105,"status":34,"city":124,"state":19,"zip":125,"country":108,"countryCode":109,"cosmosGeoPoint":126,"geoPoint":130,"contacts":19},"Lille","59037",{"type":41,"coordinates":127},[128,129],3.05512,50.63391,{"lat":129,"lon":128},{"facility":105,"status":34,"city":132,"state":132,"zip":133,"country":134,"countryCode":135,"cosmosGeoPoint":136,"geoPoint":140,"contacts":19},"Chiba","2608677","Japan","JP",{"type":41,"coordinates":137},[138,139],140.11667,35.6,{"lat":139,"lon":138},{"facility":105,"status":34,"city":142,"state":19,"zip":143,"country":134,"countryCode":135,"cosmosGeoPoint":144,"geoPoint":148,"contacts":19},"Kyoto","6068507",{"type":41,"coordinates":145},[146,147],135.75385,35.02107,{"lat":147,"lon":146},{"facility":105,"status":34,"city":150,"state":151,"zip":152,"country":153,"countryCode":154,"cosmosGeoPoint":155,"geoPoint":159,"contacts":19},"Sheffield","South Yorkshire","S10 2JF","United Kingdom","UK",{"type":41,"coordinates":156},[157,158],-1.4659,53.38297,{"lat":158,"lon":157},{"facility":105,"status":34,"city":161,"state":19,"zip":162,"country":153,"countryCode":154,"cosmosGeoPoint":163,"geoPoint":167,"contacts":19},"London","SE5 9RS",{"type":41,"coordinates":164},[165,166],-0.12574,51.50853,{"lat":166,"lon":165},{"type":169,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100570209","phase-1-study-to-assess-safety-efficacy-and-cellular-kinetics-of-ytb323-in-generalized-myasthenia-gravis-100570209",false,"NCT06704269","Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis","An Open-label, Multi-center, Phase I\u002FII Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Participants With Treatment-resistant Generalized Myasthenia Gravis","Inclusion Criteria:\n\n1. Confirmed gMG diagnosis supported by the following:\n\n   * Documented report of positive serology testing for either AChR antibodies or MuSK antibodies at screening AND at least one of the following:\n   * History of abnormal neuromuscular transmission test demonstrated by repetitive nerve stimulation or single-fiber electromyography\n   * History of positive acetylcholinesterase inhibitor test\n   * Improvement in MG signs on an oral acetylcholinesterase inhibitor as assessed by the treating physician\n2. MGFA Class III-IVa (gMG) at screening\n3. Treatment-resistant gMG as defined by: MG-ADL score ≥ 6 (≥50% non-ocular) at screening despite adequate treatment trials with at least two different non-steroidal immunosuppressive drugs given at adequate doses and duration of therapy.\n4. If on chronic corticosteroids, must be on a stable dose of corticosteroids for ≥1 month prior to screening and have the ability and willingness to taper to a maximum dose of 10 mg prednisolone daily or equivalent at least one week before leukapheresis\n5. If treated with cholinesterase inhibitors, patients must be on a stable dose for at least two weeks prior to screening\n\nExclusion Criteria:\n\n1. Exclusively ocular myasthenia gravis (MGFA I), mild symptoms (MGFA II), or severe bulbar disease or MG crisis, MGFA Class IVb or V at screening\n2. History of bone marrow\u002Fhematopoietic stem cell or solid organ transplantation.\n3. Clinically significant active, opportunistic, chronic or recurrent infection (including positive for hepatitis B or hepatitis C) confirmed by clinical evidence, imaging, or positive laboratory tests one month prior to leukapheresis\n4. Other uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids, at screening\n5. Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for HIV antibody, at screening\n6. Prior treatment with anti-CD19 therapy, adoptive T cell therapy or any prior gene therapy product (e.g. CAR-T cell therapy).\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years","65 Years",{"count":181,"type":182},15,"ESTIMATED","INTERVENTIONAL",[185,186],"PHASE1","PHASE2","This is a phase I\u002FII study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a Biological CAR-T cell therapy.",[189],"Generalized Myasthenia Gravis",[191,192,9,193],"myasthenia gravis","generalized myasthenia gravis","CAR-T","2026-06-25",{"date":196,"type":197},"2026-06-26","ACTUAL",{"date":199,"type":197},"2025-04-22",{"date":201,"type":182},"2029-10-26",{"name":22,"class":6},11]